Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology

Ishigami, Shuta; Ohtsuki, Shinichi; Eitoku, Takahiro; Ousaka, Daiki; Kondo, Maiko; Kurita, Yoshihiko; Hirai, Kentaro; Fukushima, Yukio; Baba, Kenji; Goto, Takuya; Horio, Naohiro; Kobayashi, Junko; Kuroko, Yosuke; Kotani, Yasuhiro; Arai, Sadahiko; Iwasaki, Tadaaki; Sato, Shuhei; Kasahara, Shingo; Sano, Shunji; Oh, Hidemasa

doi:10.1161/circresaha.116.310253

Cited by 132 publications

(53 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest study to date, PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease), is a randomized phase 2 study focusing on autologous cardiospherederived cells and intracoronary delivery of 3.0×10 5 cells/kg months after either stage 2 or stage 3 palliation. 89 The cardiosphere-derived cells require 3 to 4 weeks of expansion after right atrial samples are being processed from the prior surgery. The conclusions of this study with 41 patients in a 1:1 ratio demonstrates measurable improvements in cardiac function within 3 months after cell infusion without attributable adverse events other than transient ST-segment changes with cardiac enzyme leak and procedure-related hypotension.…”

Section: Cell-based Therapies For Chdmentioning

confidence: 99%

Current Interventional and Surgical Management of Congenital Heart Disease

Holst

Said

Nelson

et al. 2017

Circulation Research

View full text Add to dashboard Cite

Successful outcome in the care of patients with congenital heart disease depends on a comprehensive multidisciplinary team. Surgery is offered for almost every heart defect, despite complexity. Early mortality for cardiac surgery in the neonatal period is ≈10% and beyond infancy is <5%, with 90% to 95% of patients surviving with a good quality of life into the adult years. Advances in imaging have facilitated accurate diagnosis and planning of interventions and surgical procedures. Similarly, advances in the perioperative medical management of patients, particularly with intensive care, has also contributed to improving outcomes. Arrhythmias and heart failure are the most common late complications for the majority of defects, and reoperation for valvar problems is common. Lifelong surveillance for monitoring of recurrent or residual structural heart defects, as well as periodic assessment of cardiac function and arrhythmia monitoring, is essential for all patients. The field of congenital heart surgery is poised to incorporate new innovations such as bioengineered cells and scaffolds that will iteratively move toward bioengineered patches, conduits, valves, and even whole organs.

show abstract

Section: Cell-based Therapies For Chdmentioning

confidence: 99%

Current Interventional and Surgical Management of Congenital Heart Disease

Holst

Said

Nelson

et al. 2017

Circulation Research

View full text Add to dashboard Cite

show abstract

“…immediate and long-term cardiac function and heart failure status following administration of cardiac stems cells at the time of surgical palliation. 57,58 These results, namely, the improvement in right ventricular function, may be informative as to the potential for application in newborns with AS-eHLHS as a further support for maintaining biventricular circulation in the newborn period. This area of stem cells however remains controversial with an increase in a wide range of stem cell therapies of a wide range of disorders without little regulation or documentation of the stem cell origin.…”

Section: Hlhs Multiple Trials Have Now Demonstrated Improvement In Bothmentioning

confidence: 89%

Fetal cardiac intervention—Perspectives from a single center

2020

View full text Add to dashboard Cite

Fetal cardiac intervention was first proposed in the early 1990s to impact cardiac development and survival of fetuses with fetal aortic stenosis and evolving hypoplastic left heart syndrome (HLHS). Although initial attempts of fetal aortic valvuloplasty were unsuccessful and carried a high rate of morbidity and mortality, our collaborative group at the Brigham and Women's Hospital and Boston Children's Hospital have reinvigorated the procedure using improvements in imaging, anesthesia, balloon catheters, and surgical techniques. Two decades of experience have now allowed us to document the safety of in utero intervention and to achieve a better understanding of the impact of midgestation intervention on developing HLHS. Research into underlying genetics, predictive biomarkers, and ways to incorporate stem cell technology will hopefully allow us to further refine the procedure to most benefit children with this historically lethal disease.

show abstract

“…Based on these results, a phase II trial (PERSEUS, cardiac progenitor cell infusion to treat univentricular heart disease) was conducted, and the results were published recently. 34 This trial was a randomized-controlled study, and a total of 34 patients with SV physiology were enrolled. The efficacy of the intracoronary delivery of autologous CDCs after second-stage or third-stage palliation was evaluated.…”

Section: Regenerative Therapy For Heart Failurementioning

confidence: 99%

Regenerative Therapy for Patients with Congenital Heart Disease

Kimura

2018

Keio J. Med.

View full text Add to dashboard Cite

Congenital heart disease (CHD) is the most common birth defect, affecting 1 in 100 babies. Among CHDs, single ventricle (SV) physiologies, such as hypoplastic left heart syndrome and tricuspid atresia, are particularly severe conditions that require multiple palliative surgeries, including the Fontan procedure. Although the management strategies for SV patients have markedly improved, the prevalence of ventricular dysfunction continues to increase over time, especially after the Fontan procedure. At present, the final treatment for SV patients who develop heart failure is heart transplantation; however, transplantation is difficult to achieve because of severe donor shortages. Recently, various regenerative therapies for heart failure have been developed that increase cardiomyocytes and restore cardiac function, with promising results in adults. The clinical application of various forms of regenerative medicine for CHD patients with heart failure is highly anticipated, and the latest research in this field is reviewed here. In addition, regenerative therapy is important for children with CHD because of their natural growth. The ideal pediatric cardiovascular device would have the potential to adapt to a child's growth. Therefore, if a device that increases in size in accordance with the patient's growth could be developed using regenerative medicine, it would be highly beneficial. This review provides an overview of the available regenerative technologies for CHD patients.

show abstract

Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology

Abstract: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01829750.

Cited by 132 publications

References 33 publications

Current Interventional and Surgical Management of Congenital Heart Disease

Current Interventional and Surgical Management of Congenital Heart Disease

Fetal cardiac intervention—Perspectives from a single center

Regenerative Therapy for Patients with Congenital Heart Disease

Contact Info

Product

Resources

About